Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by stockgambleron Sep 04, 2007 11:58am

261 Views

Post# 13339195

RE: Credibility issue with DM

"Talked to Don last week, he was insistant that everything was going great. Nothing to hold the stock back now, momentum in our favor, jump in now or it may be too late. I wonder if DM knew or remembered he just signed a renegotiation financing that basically said his Company stock should be worth $8.76. Don has lied to me for the last time! I am now a shorter!. " Ouch...

Bullboard Posts

How one company is disrupting PoC testing